Bausch Health Cos (BHC) Stock Price, News & Analysis

Company Overview

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices. Bausch + Lomb is also active in aesthetics with products used in ophthalmic surgery and ocular cosmetics. In its Diversified Brands segment, the company delivers a portfolio of dermatology treatments for both prescription and consumer use, gastrointestinal therapies for irritable bowel syndrome and ulcerative colitis, as well as neurology products targeting migraine prevention and treatment.

Tracing its roots back to a Canadian pharmaceutical firm founded in 1959, the company underwent significant expansion after acquiring Bausch + Lomb in 2013 under the Valeant name. In May 2018, the enterprise rebranded as Bausch Health Companies Inc to reflect a renewed focus on core pharmaceutical and eye health operations. Today, it maintains manufacturing sites and research facilities across North America, Europe, Latin America and Asia-Pacific, serving patients and healthcare professionals in more than 100 countries.

Under the leadership of President and Chief Executive Officer Joseph C. Cacciatore, Bausch Health has pursued portfolio optimization, debt reduction and a disciplined approach to research and development. The company continues to invest in its pipeline of specialty medicines and eye health solutions, while seeking to enhance access to care through strategic partnerships and targeted licensing agreements around the world.

Key Stats

• Today's Range: $4.89 to $5.05
• 50-Day Range: $4.96 to $5.92
• 52-Week Range: $4.89 to $8.69
• Volume: 2.14 million shs
• Average Volume: 1.99 million shs
• Market Capitalization: $1.85 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.00
• Consensus Rating: Reduce

Bausch Health Cos Stock Analysis - MarketRank™

Bausch Health Cos scored higher than 58% of companies evaluated by MarketBeat, and ranked 419th out of 855 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Reduce

Consensus Rating

Bausch Health Cos has received a consensus rating of Reduce. The company's average rating score is 1.80, and is based on no strong buy ratings, no buy ratings, 4 hold ratings, and 1 sell rating.

Upside Potential

Bausch Health Cos has a consensus price target of $8.00, representing about 61.5% upside from its current price of $4.96.

Amount of Analyst Coverage

Bausch Health Cos has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: -7.35%

Earnings Growth

Earnings for Bausch Health Cos are expected to decrease by -7.35% in the coming year, from $4.08 to $3.78 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Bausch Health Cos is -1.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bausch Health Cos is -1.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Bausch Health Cos has a P/B Ratio of 4.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.07% of the float of Bausch Health Cos has been sold short.

Short Interest Ratio / Days to Cover

Bausch Health Cos has a short interest ratio ("days to cover") of 3.82, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bausch Health Cos has recently increased by 2.66%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bausch Health Cos does not currently pay a dividend.

Dividend Growth

Bausch Health Cos does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.95

News Sentiment

Bausch Health Cos has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Bausch Health Cos this week, compared to 3 articles on an average week.

Search Interest

10 people have searched for BHC on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.

MarketBeat Follows

3 people have added Bausch Health Cos to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Bausch Health Cos insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $132,796.00 in company stock.

Percentage Held by Insiders

20.67% of the stock of Bausch Health Cos is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

78.65% of the stock of Bausch Health Cos is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 4/29/2026
• Today: 6/16/2026
• Next Earnings (Estimated): 7/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED - GENERIC DRG
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:BHC
• CIK: 885590
• Web: www.bauschhealth.com
• Phone: (514) 744-6792
• Fax: 514-744-6272
• Employees: 20,300
• Year Founded: 1959

Price Target and Rating

• Average Price Target for Bausch Health Cos: $8.00
• High Price Target: $9.00
• Low Price Target: $7.00
• Potential Upside/Downside: +61.5%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.24)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 1.21
• P/E Growth: N/A
• Net Income: $157 million
• Net Margins: -11.47%
• Pretax Margin: -8.93%
• Return on Equity: -2,922.77%
• Return on Assets: 5.63%

Debt

• Debt-to-Equity Ratio: 54.68
• Current Ratio: 1.32
• Quick Ratio: 0.97

Sales & Book Value

• Annual Sales: $10.27 billion
• Price / Sales: 0.18
• Cash Flow: $7.18 per share
• Price / Cash Flow: 0.69
• Book Value: $1.02 per share
• Price / Book: 4.86

Miscellaneous

• Outstanding Shares: 374,020,000
• Free Float: 296,713,000
• Market Cap: $1.85 billion
• Optionable: Optionable
• Beta: 0.40